Fluvirin FDA Manufacturing Inspections Expected By July
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive outcome of FDA inspections this summer would be final barrier to re-introducing Fluvirin to the U.S. market. Earlier suspension by U.K. health authorities will not dampen demand for vaccine, Chiron says; the company expects to manufacture 25 mil.-30 mil. doses for 2005/2006 flu season.
You may also be interested in...
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Chiron, GSK Flu Vaccine Availability May Not Be Clear Until August, CDC Says
Due to uncertainty about the number of vaccine suppliers, the agency has devised an immunization strategy based on three supply scenarios for the 2005-2006 influenza season. The strategy places individuals into tiers based upon their age, health status and contact with persons at high risk.
Chiron, GSK Flu Vaccine Availability May Not Be Clear Until August, CDC Says
Due to uncertainty about the number of vaccine suppliers, the agency has devised an immunization strategy based on three supply scenarios for the 2005-2006 influenza season. The strategy places individuals into tiers based upon their age, health status and contact with persons at high risk.